Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Revolutionary silk-based bioink for 3D printing of ex vivo bone marrow models to advance drug development and personalized medicine

Project description

Innovative bio-ink for 3D printing crucial bone marrow models

Bone marrow diseases impact a substantial portion of the population, making it a complex field for both the development of new medicines and research. The EIC-funded SILKink project will address this challenge by creating an innovative bio-ink using silk as a base material. This bio-ink can then be used for 3D printing highly accurate models of bone marrow tissue in various sizes and shapes, or for simulating haematopoietic stem and progenitor cells. By doing so, this advancement could greatly enhance medical research and facilitate the creation of tailored drugs and personalised medical treatments for individual patients.

Objective

Aim: The SILKink project aims to develop a breakthrough biocompatible hydrogel, i.e. a bioink, to 3D print bone marrow tissue models that can be used for robust culture of human stem cells. The use of silk as the basis for novel bioinks (SILKink) helps to recreate tailored bone marrow-like microenvironments that will enable new applications in drug development and personalized medicine for bone marrow diseases. Here, we aim to optimize and validate SILKink, further define the business opportunity, and found an investment-ready spin-off company to commercialize SILKink.
Unmet need: Bone marrow stem cells are fragile and require highly specific surroundings to survive and differentiate, therefore the presence of a soft tissue environment mimicking the human bone marrow is critical for reproducible culturing of these cells. There is a large unmet need for reproducible solutions that mimic the soft tissue of the bone marrow to allow advancements in drug development and personalized medicine approaches for bone marrow diseases.
Solution: We will develop SILKink: a revolutionary bioink that is uniquely based on silk to closely mimic the 3D soft tissue environment of the bone marrow. SILKink will provide a matrix that supports all bone marrow cells including hematopoietic stem and progenitor cells and allows to 3D print ex vivo bone marrow stem cell models in the shape or volume desired.
Consortium: University of Pavia (UNIPV) and partner CELLINK have developed the SILKink prototype during FET Open project SilkFUSION and co-own the background IP. Partner Catalyze-Group – Venture Building Team (CAT) will bring commercial expertise to develop an optimal market access strategy for SILKink. UNIPV will be responsible for SILKink optimization, manufacturing, and validation. CELLINK will be involved in product optimization and responsible for product development. CAT will assist UNIPV with founding a spin-off company to commercialize SILKink and making it investment-ready.

Fields of science (EuroSciVoc)

This project has not yet been classified with EuroSciVoc.
Be the first one to suggest relevant scientific fields and help us improve our classification service

Keywords

Programme(s)

Topic(s)

Funding Scheme

HORIZON-EIC - HORIZON EIC Grants

See all projects funded under this funding scheme

Call for proposal

(opens in new window) HORIZON-EIC-2022-TRANSITION-01

See all projects funded under this call

Coordinator

UNIVERSITA DEGLI STUDI DI PAVIA
Net EU contribution
€ 1 111 250,00
Address
STRADA NUOVA 65
27100 Pavia
Italy
Region
Nord-Ovest Lombardia Pavia
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 423 750,00

Participants (3)